Joint Clinical Trials Office

Trial No Longer Available

This trial is no longer open to enrollment. Please consider searching our Open Clinical Trial Database for currently available studies.

Daratumumab, Pomalidomide and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

The purpose of this study is to assess the efficacy of this combination of drugs in light chain (AL) amyloidosis which has relapsed or become refractory to other treatments. Amyloidosis is a rare disease that is caused by a substance called amyloid. Amyloid is an abnormal protein produced by plasma cells in the bone marrow which cannot be broken down by the body and so accumulate over time in various organs. Amyloidosis can affect different organs in different people. The most commonly affected organs are the heart, kidney, liver, spleen, nervous system, and digestive tract.

Multimodal Neuroimaging in Traumatic Brain Injury

We are looking for people to participate in a Weill Cornell research study using Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) to better understand brain processes that may make Traumatic Brain Injury (TBI) a risk factor for later development of Alzheimer’s Disease or Chronic Traumatic Encephalopathy (CTE).


Research study participation lasts up to two years and involves:

A Pilot Study of Rimegepant in Moderate Plaque-type Psoriasis

This research study is being done because there is a need for systemic therapies for moderately severe plaque-type psoriasis that are both effective and have minimal side effects.

Single-Arm Phase II Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy with Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer

The primary goal of this study is to assess whether using recent advances in technology to treat high intermediate risk and high-risk prostate cancer (HrPCa) can improve clinical outcomes, measured as recurrence-free survival at 2 years after treatment.

Will it cost me anything to be in this study?

No. You will be compensated for your time and effort.

Are there risks or side effects?

Yes. Potential risks and side effects will be discussed with you in detail before you decide to join the study.

Why would Leuprolide help with Alzheimer’s Disease?

Prior research in animals and humans suggests that Leuprolide helps with Alzheimer’s Disease via several mechanisms including regulation of brain cell replication and reduction of inflammation.

What is Leuprolide normally used for?

Leuprolide is approved by the FDA for treatment of prostate cancer in men, endometriosis in women and early puberty in children. It is also commonly used in women preparing for in vitro fertilization. LUCINDA aims to repurpose Leuprolide for Alzheimer's Disease. 

Who can join this study?

This study is open to women over age 60 diagnosed with Mild Cognitive Impairment or Alzheimer’s Disease who are taking a stable dose of a cholinesterase inhibitor such as donepezil (Aricept) Participants must have a study partner (friend, family member or caregiver) who spends at least ten hours per week with them and can participate in all study visits.